English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Medicine Clinical Trials
OBI-902 has been granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Nov 17, 2025 20:00 HKT
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
Oct 14, 2025 17:38 HKT
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 15:00 HKT
WORK Medical enters strategic partnerships in bid to explore RWA initiatives
Sep 24, 2025 22:30 HKT
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 12:15 HKT
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sep 15, 2025 15:19 HKT
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation
Aug 26, 2025 20:00 HKT
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 HKT
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
Jul 25, 2025 10:52 HKT
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets
Jul 22, 2025 13:00 HKT
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025 21:27 HKT
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 18:43 HKT
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA
Apr 15, 2025 08:00 HKT
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Mar 25, 2025 23:34 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: